CPHI WORLDWIDE 2017

Continuous manufacturing: suitable excipients & more knowledge required, says Dow

By Flora Southey contact

- Last updated on GMT

gettyimages/sinemaslow
gettyimages/sinemaslow

Related tags: Continuous manufacturing, Food and drug administration, Pharmacology

Drug firms need excipients suited to continuous manufacturing according to Dow, which says a better understanding of how products perform when used in round-the-clock production is required.

Continuous manufacturing is one of the biggest trends in solid form manufacturing, said Dow’s Amina Faham at CPhI Worldwide’s Pre-Connect Congress on Monday.

However, making solid dose forms requires a large amount of excipients, and not enough is known about the impact of raw materials on flow rate consistency and homogeneity in the continuous process, she said.

“Existing excipients may not be able to address all the needs of the continuous process,” ​said Faham

“There is a clear need for excipients that are designed for the purpose of the continuous process,” ​she added.

According to Faham, improved knowledge of raw materials could improve product quality.

“A better understanding and better control of all the key attributes of raw materials – excipients and APIs ​[active pharmaceutical ingredients] – and how they impact the manufacturability, and quality of the final drug product, is needed,” ​she said.

The continuous method – said​ to improve speed and quality in drug production – is gaining support across Europe and the US.

In 2016, the US Food and Drug Administration (FDA) was the first regulator to approve​ Janssen’s continuous manufacturing method for HIV drug Prezista (darunavir).

Since then, Swissmedic and the European Medicines Agency​ (EMA) have also cleared Janssen’s move from the traditional ‘batch’ approach to make Prezista.

Related news

Show more

Related products

show more

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

SQ-USP-Brochure-Thumb-AP-CC

NEW…sugarcane derived USP Squalane from Aprinnova

APRINNOVA – A joint venture of AMYRIS and NIKKOL Group | 26-Feb-2018 | Product Brochure

To date, topical formulation chemists have been restricted to using Squalane derived from the harvesting of shark livers. Neossance Squalane USP, derived...

Roquette Oral Dose Case Study - Part IV

Roquette Oral Dose Case Study - Part IV

Roquette Pharma Solutions | 04-Dec-2017 | Case Study

Download the latest Roquette case study and learn more on how PEARLITOL® Flash mannitol and starch compound offers inert stability, fast disintegration...

Roquette Oral Dose Case Study - Part III

Roquette Oral Dose Case Study - Part III

Roquette Pharma Solutions | 27-Nov-2017 | Case Study

Download the Case Study to find out how Roquette’s SweetPearl® P 300 DC maltitol technology makes an effervescent tablet solution attractive and palatable...

Related suppliers